Investment Rating - The report maintains a strong investment rating for the pharmaceutical and biotechnology sector, indicating it is expected to outperform the market [5]. Core Insights - The report highlights the upcoming IPO of Ying'en Biotech, a newcomer in the ADC field, with significant potential in its core pipeline products [2][20]. - The company has secured product authorizations with multiple partners, including BioNtech and GSK, with a total collaboration value exceeding $6 billion [3][23]. - The report emphasizes the importance of innovation in the pharmaceutical sector, particularly in the context of the ongoing tariff disputes, which are expected to have a limited impact on the industry [4][5]. Summary by Sections Market Review - The CITIC Pharmaceutical Index fell by 5.4% during the week of April 7-11, 2025, underperforming the CSI 300 Index by 2.5 percentage points [3]. - The pharmaceutical and biotechnology sector has seen a decline of 1.0% year-to-date, outperforming the CSI 300 Index by 3.7 percentage points [3]. Ying'en Biotech Overview - Ying'en Biotech's IPO process includes public offerings starting April 7, 2025, with shares expected to begin trading on April 15, 2025 [3][20]. - The company's core pipeline includes DB-1303 (HER2 ADC) and DB-1311 (B7-H3 ADC), with DB-1303 expected to submit for accelerated approval to the FDA in 2025 [3][20][26]. - DB-1311 is currently in Phase IIa trials, showing promising results in prostate cancer with an overall response rate (uORR) of 28.0% and a disease control rate (DCR) of 92.0% [3][4]. Product Pipeline and Collaborations - Ying'en Biotech has a robust pipeline with several ADC products in various clinical stages, including DB-1305 (TROP2 ADC) and DB-1310 (HER3 ADC) [4][20]. - The company has established collaborations with major pharmaceutical companies, which include significant milestone payments and revenue-sharing agreements [23][25]. - The report notes that the HER2 ADC market is competitive, but Ying'en Biotech's DB-1303 has a potential leading advantage in endometrial cancer indications [41][42]. Investment Strategy - The report suggests focusing on innovation as a key investment strategy, particularly in the context of the ongoing tariff disputes and the need for supply chain security [4][5]. - It recommends a diversified investment approach, including innovative biopharma and consumer healthcare sectors, to capitalize on domestic demand stimulation [4][5].

证券研究报告 | 医药生物 | 2025年4月12日 www.hczq.com 华创医药投资观点&研究专题周周谈·第121期 海外CXO 2024财报总结 本周周专题联系人：万梦蝶 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号: S0360523080008 邮箱: wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号：S0360524070007 邮箱 ...

医药生物行业今日上涨2.03%，全天主力资金净流出6.86亿元，该行业所属的个股共476只，今日上涨的 有459只，涨停的有6只；下跌的有13只。以资金流向数据进行统计，该行业资金净流入的个股有192 只，其中，净流入资金超3000万元的有8只，净流入资金居首的是恒瑞医药，今日净流入资金1.29亿 元，紧随其后的是泰格医药、永安药业，净流入资金分别为6531.50万元、4910.80万元。医药生物行业 资金净流出个股中，资金净流出超5000万元的有6只，净流出资金居前的有派林生物、翰宇药业、天坛 生物，净流出资金分别为1.14亿元、9298.74万元、7631.74万元。（数据宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 600276 | 恒瑞医药 | 0.58 | 1.15 | 12892.29 | | 300347 | 泰格医药 | 0.67 | 2.46 | 6531.50 | | 002365 | 永安药业 | 6.10 | 27.61 | 4910.80 ...

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology industry [5]. Core Viewpoints - The report highlights the increasing external uncertainties following the US-China tariff conflict and expresses optimism towards domestic circulation and safe-haven assets in the pharmaceutical sector [2][20]. - The demand for blood products is relatively inelastic, and the recent tariff increases may lead to a short-term rise in imported albumin prices, benefiting domestic companies. The blood products industry is characterized by rigid demand and strategic resource attributes, suggesting a favorable competitive landscape for domestic alternatives [21]. - The report emphasizes the shift from "efficiency-first" to "safety-first" in supply chains, driven by the need for supply chain security, which may catalyze domestic replacements in high-end medical devices and scientific instruments [22][24]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index rose by 1.20%, outperforming the CSI 300 index by 2.57 percentage points and the ChiNext index by 3.55 percentage points, ranking third among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Medical Health Index increased by 1.32%, surpassing the Hang Seng Index by 3.49 percentage points [1][16]. Company Updates - Recent developments include the new listing application for SHR2554 tablets by Heng Rui Medicine and clinical application advancements for several products from Heng Rui Medicine and Lepu Biopharma [27]. Investment Strategy - The report suggests focusing on three main directions: policy support for hospital payments (innovative drugs and devices), expansion of public demand (blood products, home medical devices, weight loss drug supply chains), and an upward cycle for overseas payments (heparin, respiratory joint inspections) [24]. Key Company Profit Forecasts and Valuations - Key companies such as Mindray Medical, United Imaging, and Yuyue Medical are highlighted with projected earnings per share (EPS) and price-to-earnings (PE) ratios indicating a "Buy" recommendation [4]. Important Database Updates - The cumulative total number of hospital diagnoses showed a year-on-year increase of 13.29%, with significant growth in tertiary hospitals [30]. - The pharmaceutical manufacturing industry reported a year-on-year revenue decline of 3.4% for the first two months of 2025, with total revenue of 369.43 billion yuan [60].

Group 1: Policy Support for Pharmaceutical Innovation - Beijing encourages local production of innovative pharmaceuticals, supporting enterprises in importing significant drug and medical device varieties, and promoting the industrialization and large-scale application of innovative products [1] - Shenzhen offers financial incentives for innovative drugs that complete clinical trials and achieve domestic and international market entry, with rewards up to 30 million yuan based on clinical trial phases [2] Group 2: Company Developments - Heng Rui Medicine grants exclusive commercialization rights of its new drug SHR7280 to Germany's Merck, receiving an upfront payment of 15 million euros and potential milestone payments and sales royalties [3] - East China Pharmaceutical's subsidiary receives approval for clinical trials of DR30206, a novel antibody fusion protein targeting PD-L1, VEGF, and TGF-β, marking a significant advancement in its development [4] Group 3: Market Trends and Opportunities - Blood product stocks, including Wei Guang Bio and Pai Lin Bio, experience a surge due to the rigid demand for blood products and potential price increases from U.S. tariffs, benefiting domestic companies and presenting strategic opportunities for market share growth [6]

4月7日，上证指数下跌7.34%，深证成指下跌9.66%，创业板指下跌12.5%。盘后龙虎榜数据显示，共有 60只个股因当日异动登上龙虎榜，资金净流入最多的是宏景科技（301396.SZ），达2.04亿元。 据21投资通智能监测，32只个股龙虎榜出现了机构的身影，北向资金参与龙虎榜中的个股共涉及18只。 2.04亿资金抢筹宏景科技，9.45亿资金出逃中际旭创 60只上榜的龙虎榜个股中，30只个股被净买入，30只个股被净卖出。其中，资金净买入最多的是宏景科 技，达2.04亿元，占总成交金额的14.04%。宏景科技当日收盘下跌13.42%，换手率为34.73%。 | 名称 | 涨跌幅 | 龙虎榜净买 | 净买额占 | 换丰浓 | | | --- | --- | --- | --- | --- | --- | | | | 额(万元 | 总成交比 | | | | 宏景科技 | -13.42% | 20444 | 14.04% | 34.73% | 2家机构卖出,成功 | | | | | | | 率36.92% | | 凯美特气 | 9.99% | 17123 | 7.3% | 32.28% | 普通席位买入,成功 | ...

Market Overview - The Asia-Pacific stock markets experienced a significant decline, with the Nikkei 225 index dropping 7.83% to close at 31,136.58 points, and the South Korean Composite Index falling 5.57% to 2,328.03 points, marking a new low for November 2023 [1] - The Australian S&P 200 index decreased by 3.89% to 7,369.4 points, while the New Zealand S&P 50 index fell 3.68% to 11,775.88 points. The Hong Kong Hang Seng Index plummeted over 13%, falling below the 20,000-point mark, and the Hang Seng Tech Index dropped over 17% [1] - European markets also faced declines, with the Euro Stoxx 50 index down over 5%, and major indices like Germany's DAX, France's CAC40, and Italy's FTSE MIB all dropping more than 6% [1][2] A-Share Market Performance - The A-share market saw widespread losses, with the Shanghai Composite Index plunging 7.34% to 3,096.58 points, and the Shenzhen Component Index falling 9.66% to 9,364.5 points. The ChiNext Index dropped 12.5% to 1,807.21 points, and the North Star 50 Index fell nearly 18% [2] - Approximately 5,300 stocks in the A-share market were in the red, with around 3,000 stocks hitting the daily limit down, indicating a severe market downturn [3] Sector Performance - The semiconductor sector experienced significant declines, with stocks like Guomian Technology, Jiangbolong, and Weir Shares hitting the daily limit down [6] - The pharmaceutical sector also saw a drop of over 10%, with companies such as Boteng Co., Jincheng Pharmaceutical, and WuXi AppTec facing substantial losses [5] - Conversely, the blood products sector showed resilience, with companies like Palin Bio and Weiguang Bio hitting the daily limit up, driven by the inelastic demand for blood products and potential price increases due to tariffs on imports [8] Investment Strategies - Analysts suggest that the current market conditions may lead to a continued period of volatility, with a focus on stable dividend strategies and sectors benefiting from domestic demand policies [11] - Emphasis is placed on identifying high-quality companies with stable earnings, particularly in sectors with strong domestic market demand [11] - The impact of tariff policies on various sectors, including agriculture and semiconductor materials, is highlighted, with recommendations to focus on sectors with strong performance certainty and low valuations [11]

Core Viewpoint - The recent imposition of a 34% tariff on U.S. imports by China is expected to benefit domestic blood product companies, as it may lead to a price increase for imported human albumin, thereby enhancing the market share of domestic products [3][4]. Group 1: Market Impact - The demand for blood products is relatively inelastic, and the tariff is unlikely to significantly affect overall demand due to its essential nature [4]. - China imports over 60% of its human albumin products, with the U.S. being a major supplier, exporting $54.6 billion in blood products in 2024 [4]. - The price of imported human albumin is expected to rise, reducing its competitive advantage over domestic products, which may lead to an increase in market share for local companies [5]. Group 2: Pricing Dynamics - As of April 6, 2025, domestic human albumin prices are slightly higher than imported ones, but the tariff may eliminate the price advantage of imports [5]. - For example, the price range for imported human albumin (10g specification) is between 345-438 RMB, while domestic products range from 359-580 RMB [5]. Group 3: Supply Chain and Industry Structure - The blood product industry is characterized by a limited number of manufacturers, creating an oligopoly with companies like Tian Tan Bio, Shanghai Raist, and Hualan Biological [6]. - The industry is less affected by geopolitical risks due to its self-sufficient supply chain and the nature of its products [6][7]. - The ongoing trade tensions may enhance the internal circulation advantages of the blood product industry, supporting its long-term growth prospects [7].

Group 1 - The blood products sector is experiencing growth, with companies like Shijiazhuang Yiling Pharmaceutical, Palin Bio, Boya Bio, and Tiantan Bio seeing stock price increases [1] - Shanxi Securities reported strong demand for immunoglobulin and albumin, with a projected market share of 6.5% and 2.5% for the company in 2023, respectively [1] - The domestic market for immunoglobulin is expanding, and the company is expected to benefit from the launch of new generation immunoglobulin products [1] Group 2 - Boya Bio aims to achieve a plasma collection of 630.6 tons in 2024, representing a year-on-year growth of 10.4%, with its main facility collecting 522.04 tons, up 11.7% [1][2] - The company is committed to compliance and operational efficiency, expecting double-digit growth in plasma collection by 2025 [1][2] - The blood products industry has not yet been included in national centralized procurement, but local and regional procurement initiatives have begun since January 2022 [2] Group 3 - Boya Bio is focusing on international expansion through product registration and technical cooperation, aiming to increase market share for immunoglobulin and factor VIII products [2] - The company is advancing innovative treatments for rare diseases, including small nucleic acids and gene therapies, to enhance its global presence [2] - The company’s president emphasized a focus on optimizing plasma utilization and enhancing product structure to improve profitability [3]

Investment Rating - The report maintains a "Recommended" rating for the industry, indicating a positive outlook for the sector's fundamentals and expectations for the industry index to outperform the benchmark index [4]. Core Insights - The pharmaceutical industry is primarily driven by domestic demand, with most sub-sectors minimally affected by tariff impacts, such as medical services, innovative domestic drugs, traditional Chinese medicine, and pharmacy/retail [1][3]. - There is significant potential for import substitution in high-import sectors like blood products, certain medical devices, and key components, which are expected to benefit marginally from the current tariff situation [1]. - The report highlights specific sectors to watch, including blood products, domestic consumption-related sectors, and medical devices, which are poised for growth due to favorable policies and market conditions [2]. Summary by Relevant Sections Blood Products - The overseas share of human albumin exceeds 60%, and with tariffs on imported albumin, domestic prices are expected to recover. The "14th Five-Year Plan" for new plasma stations is also promising. Companies to focus on include Palin Biotech, Tiantan Biological, and Boya Biological [2]. Domestic Consumption - External impacts are minimal, and consumption policies are catalyzing recovery in certain areas. Key companies include medical services (e.g., Aier Eye Hospital, Tongce Medical), beauty services (Aimeike), pharmacies (Yifeng Pharmacy, Dazhong Pharmacy), and traditional Chinese medicine (Dong-E E-Jiao, China Resources Sanjiu) [2]. Medical Devices - For core components, the domestic market for medical CT tubes is largely dominated by imports, with potential benefits from anti-dumping investigations. Companies to watch include Yirui Technology and United Imaging Healthcare [2]. - In consumables, the domestic market for electrophysiology is under 10% localization, with U.S. companies leading. Companies like Huitai Medical and Microelectrophysiology are expected to benefit from increased localization [2]. - In vitro diagnostics (IVD) are also highlighted, with certain leading foreign companies facing tariffs that may accelerate import substitution. Recommended companies include New Industries, Mindray Medical, Antu Biology, and Yanhui Long [2]. Pharmaceuticals - The report indicates that the pharmaceutical sector is largely unaffected by tariffs, with a focus on domestic innovation. Companies to monitor include Heng Rui Medicine, Innovent Biologics, and Fuhong Hanlin [3].